FEB 102006 g IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Dirk STENKAMP, et al U.S. Appln. No. : 10/647,156

TENKAMP, et al) Art Unit: 156) Examiner:

1614 Tamthom Ngo TRUONG

Confirmation No. : 1272

U.S. Filing Date : August 22, 2003

Title of Invention: NEW CARBOXAMIDE COMPOUNDS HAVING MELANIN
CONCENTRATING HORMONE ANTAGONISTIC ACTIVITY,

PHARMACEUTICAL PREPARATIONS COMPRISING THESE COMPOUNDS AND PROCESS FOR THEIR MANUFACTURE

Attny. Docket No.: 1/1387

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

February 7, 2006

SUPPLEMENTAL TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an informal **\frac{\pi_1}{2}\). Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specific hereinbelow.

1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

02/13/2006 BABRAHA1 00000094 022955 10647156

01 FC:1806 180.00 DA

		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
§1.97(c	nt as s). This Statement is being filed after the period specified in 37 C.F.R. n or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e)).
	counte	Each item of information contained in the instant information disclosure ent was first cited in any communication from a foreign patent office in a rpart foreign application not more than three (3) months prior to the filing of tant information disclosure statement; or
1 1 1	foreigr making inform §1.56(e	No item of information contained in the instant information disclosure ent was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after greasonable inquiry, no item of information contained in the instant ation disclosure statement was known to any individual designated in 37 C.F.R.: b) more than three (3) months prior to the filing of the instant information ure statement.
[The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosu counterp	art ap	d). Each item of information contained in the accompanying information ement was cited in a communication from a foreign patent office in a plication, which communication was not received by any individual designated (c) more than thirty (30) days prior to the filing of the accompanying

2 of 3

information disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Respectfully submitted,

David A. Dow

Attorney for Applicant(s) Reg. No. 46,124

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 791-6214 Certificate of Mailing
I hereby certify that this correspondence is being deposited
with the U.S. Postal Service with sufficient postage as first
class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents

P. O. Box 1450 Alexandria, VA 223 3-1450

on February 7, 2006

David A. Dow, Reg. No. 46,124

OIPE FEB 102006 TRADEMAN

Sheet

/T.N.

Examiner Cite

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Pages, Columns, Lines, Where

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Document Number

WO 03/035055 A1

WO 03/033480 A1

er the Paperwork Reduction Act of 1995, no persons are require		tion unless it contains a valid OMB control omplete if Known	number.
	Application Number	10/647,156	
NFORMATION DISCLOSURE	Filing Date	August 22, 2003	
TATEMENT BY APPLICANT	First Named Inventor	Dirk STENKAMP	
TATEMENT BY ATTERANT	Art Unit	MAKAK 1624	
(Use as many sheets as necessary)	Examiner Name	Tamthom Ngo TRUONG	
1 0 4	Attorney Docket Number	1/1387	

Initials*	No.1	Number-Kind Code ^{2 (F Intown)}	MM-DD-Y	***	Appli	cant of Cited Document		Relevant Passages or Relevant Figures Appear	t
		US-							_
	1	US-							_
		US-							_
	1	US-							_
		US-							_
		US-	-						_
		US-							_
		US-							_
		US-							
****		US-							
		US-							
		US-							
		US-							
		US-							
		US-							_
		US-							
		US-							Т
		US-							
			FOREIGN F	PATENT	DOC	JMENTS			=
Examiner	Cite No.1	Foreign Patent Docum	nent	Publicati		Name of Patentee or		Pages, Columns, Lines,	Γ
Initials*	No.1	Country Code ³ Number ⁴ Kind Code ⁵ (If ki	nown)	MM-DD-	YYYY	Applicant of Cited Docur	nent	Where Relevant Passages or Relevant Figures Appear	1
/T.N./	\Box	WO 98/38156		09-03-	1998	TAKEDA CHEMICAL INDUST			Г
/T.N./	†	WO 02/10146 A1		02-07-	2002	SMITHKLINE BEECHAM P.L.	C.		Г
				ļ					_

U. S. PATENT DOCUMENTS

Name of Patentee or

Publication Date

/T.N./	WO 02/04433 A2	01-17-2002	NEUROGEN CO	ORPORATION	
Examiner Signature	/Tamthom Truong/			Date Considered	11/05/2009

05-01-2003

04-24-2003

SCHERING CORPORATION SMITHKLINE BEECHAM PLC

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1,97 and 1,98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1,14. This collection is estimated to take 2 hours to complete, Local Log globes; a language and the complete production of the complete pr

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Inder the Paperwork Reduction Act of 199	5 no ne	rsons are required to r		nark Office; U.S. DEPARTMENT OF COMP tion unless it contains a valid OMB control r			
	Substitute for form 1449A/PTO			Complete if Known				
				Application Number	10/647,156			
	INFORMATION DIS	CLC	SURE	Filing Date	August 22, 2003			
	STATEMENT BY A	PPI	ICANT	First Named Inventor	Dirk STENKAMP			
	OTATION ENTRY			Art Unit	XXXX 1624			
	(Use as many sheets as n	ecessar	0	Examiner Name	Tamthom Ngo TRUONG			
Sh	net 2	of	4	Attorney Docket Number	1/1387			

			U. S. PA						
Examiner Initials*	Cite No.1	Document Number	Publication MM-DD-Y	Date YYY		ame of Patentee or cant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	t
		Number-Kind Code ^{2 (F known)} US-			-			rigules Appeal	
	-	US-					┢		_
		US-	 		1		t		_
	 	US-					\vdash	1.00	_
	_	US+			-				_
		US-							_
		US-							_
		US-							
		US-							_
		US-							
		US-							_
		US-							_
		US-							
		US-							Τ
		US-							
		US+							_
		US+							
		US-							
			FOREIGN F	PATENT	DOCL	JMENTS			=
Examiner	Cite	Foreign Patent Document	ment	Publicat		Name of Patentee of		Pages, Columns, Lines,	Γ
Initials*	No.1	Country Code ³ 'Number ⁴ 'Kind Code ⁵ (#		MM-DD-	YYYY	Applicant of Cited Docu	ment	Where Relevant Passages or Relevant Figures Appear	1
/T.N./		WO 01/21169 A1		03-29-2	2001	TAKEDA CHEMICAL INDUS	TRIES,		Γ
	***********	ID 04/000000		20.00		MATCHCUITA CDADUIC			г

Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ Number (*Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	⊤ °
/T.N./		WO 01/21169 A1	03-29-2001	TAKEDA CHEMICAL INDUSTRIES, LTD.		
/T.N./		JP 01/226269	09-08-1989	MATSUSHITA GRAPHIC COMMUNIC		
/T.N./		WO 01/23365 A1	04-05-2001	MERCK PATENT GMBH		
/T.N./		WO 01/23364 A1	04-05-2001	MERCK PATENT GMBH		
/T.N./		WO 99/01127	01-14-1999	SMITHKLINE BEECHAM CORPORATION		
Examiner	Τ	/Tomthom Truonal		Date	44/05/0000	_

Examiner Signature Date Onsidered 11/05/2009 Considered 11/05/2009

"E-AVAINER: install if reterence considered, whether or not catation is in conformance with MPEP 009. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant. If Applicant's unique clatifor designation number (optionis) or USPTO Patent Documents at wheeler or wheeler or wheele

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confinentiality is operated by 35 USS. C. 122 and 37 CFR 1.14. This collection is estimated use? Journal to collection is estimated use? Journal to collection is confined to expect the confined that the confined that the confined is under the confined that th

Pages, Columns, Lines, Where

Approved for use through 07/31/2006. OMB 0651-0031

J.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Unde	r the Paperwork Reduction Act of 1995	no pe	rsons are required to re		nark Office; U.S. DEPARTMENT OF COM tion unless it contains a valid OMB control i	
		bstitute for form 1449A/PTO				mplete if Known	
					Application Number	10/647,156	
	IN	FORMATION DISC	CLC	SURE	Filing Date	August 22, 2003	
	S	TATEMENT BY AF	PL	ICANT	First Named Inventor	Dirk STENKAMP	
	_	.,	. –		Art Unit	MXX 1624	
		(Use as many sheets as ne	essar	0	Examiner Name	Tamthom Ngo TRUONG	
_	Sheet	3	Of	4	Attorney Docket Number	1/1387	

U. S. PATENT DOCUMENTS

Name of Patentee or

Publication Date

Document Number

Initials*	No.1	Number-Kind Code ^{2 (F znown)}	MM-DD-YYYY		cant of Cited Document	Relevant Pas	sages or Relevant es Appear	
		US-						
	_	US-				-		
		Us-						
		US-						
		US-						
		us-						
		US-						
		US-						
		us-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		us-						
		US-						
		F	OREIGN PATE	NT DOC	UMENTS			_
Examiner	Cite	Foreign Patent Docume	nt Publ	cation Date	Name of Patentee or	Pages, Col	umns, Lines,	
Initiels*	No.	Country Code ³ Number ⁴ Kind Code ⁵ (if kno	MM-I	D-YYYY	Applicant of Cited Docum	nent Where Rele or Relevant	vant Passages Figures Appear	1
/T.N./		WO 01/72712 A1		4-2001	COR THERAPEUTICS,			Γ
T N /	!	DE 10710101		E 1000	BOENDWOLD MOLITICAL BUND	vc		г

Initiels	No.	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	1
/T.N./		WO 01/72712 A1	10-04-2001	COR THERAPEUTICS, INC.		
/T.N./		DE 19718181	11-05-1998	BOEHRINGER INGELHEIM PHARMA KG		
/T.N./		WO 2004/039764 A1	05-13-2004	BOTHSNOER INCELNEW PHANNA GABH & CO. K		
/T.N./		WO 2005/063239 A1	07-14-2005	BOTHVINGER INSELHEM INTERNATIONAL GHOH &		
/T.N./		WO 2005/085221 A1	09-15-2005	BOEHRINGER INGELHEIM INTERNATIONAL GMBH		
_	_					=

Examiner | Date | Considered | 11/05/2009 | Tamthom Truong/ | Considered | 11/05/2009 | Considered | 11/05/2009 | Considered | 11/05/2009 | Considered | Consider

considend. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Platent Documents at www.uspto.gov or WMEP 901.04. 3 Zeiter Office that issued the document, by the two-letter code (WIPO Standard ST.3.). 4 For Japanese patient documents, the indication of the year of the reign of the Emperor must precode the serial number of the patient document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attack.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to processe) an application. Confrientiality is governed by 35 USR. C12 and 37 CFR 1.14. This collection is estimated the 2 hours to complete including anthering, preparing, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this butterd, should be sent to the Chief Indiano Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionor for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

Approved for use through 06/30/2006, ONB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

. . .

	Substitute for	TATEMENT BY APPLICANT	Complete if Known					
					Application Number	10/647,156		
	INFOR	INFORMATION DISCLOSURE		Filing Date	August 22, 2003			
	STAT	EMENT BY	'APPLI	CANT	First Named Inventor	Dirk STENKAMP		
					Art Unit	¥6524 1624		
		(Use as many sheets	as necessary,)	Examiner Name	Tamthom Ngo TRUONG		
_	Sheet	4	of	4	Attorney Docket Number	1/1387		

NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²						
/T.N./		English Abstract of JP 01/226269, Makoto K., 1989.							
/T.N./		English Abstract of DE 19718181 A1, Boehringer Ingelheim Pharma, 1998.							
			ļ						
	•••••								

$\overline{}$			
Examiner Signature	/Tamthom Truong/	Date Considered	11/05/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considerate. Include copy of this form with next communication to applicant.

In this collection of information is required by 37 CPR, 13 Page 1, 10 page